Revolution Medicines, Inc.
RVMD Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 23, 2026
$186.99
KIRA · Stoqly’s AI analyst, in plain words
- Revolution Medicines, Inc. had $0.0M of revenue in fiscal 2025.
- Revolution Medicines, Inc. lost $1.1B in fiscal 2025.
- Free cash flow was −$914M in fiscal 2025, — of revenue.
Market cap
$39.4B
P/E
—
Revenue
$0.0M
Net income
−$1.1B
Free cash flow
−$914M
Operating margin
—
Revolution Medicines, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$1.1B
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Revolution Medicines, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 25, 2026
- Legal name
- Revolution Medicines, Inc.
- CIK
- 0001628171
Revolution Medicines, Inc. · RVMD
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $29.4M | $35.4M | $11.6M | $0.0M | $0.0M |
| Revenue growth | −31.6% | 20.4% | −67.3% | −100.0% | — |
| Operating margin | −639.7% | −730.0% | −4,207.1% | — | — |
| Net income | −$187M | −$249M | −$436M | −$600M | −$1.1B |
| Net margin | −636.6% | −703.0% | −3,768.3% | — | — |
| Diluted EPS | −$2.57 | −$3.08 | −$3.86 | −$3.58 | −$5.95 |
| Cash | |||||
| Cash from operations | −$147M | −$224M | −$351M | −$557M | −$898M |
| Capital expenditure | $6.5M | $10.8M | $7.7M | $10.3M | $16.0M |
| Free cash flow | −$154M | −$235M | −$358M | −$568M | −$914M |
| FCF margin | −523.0% | −664.8% | −3,094.1% | — | — |
| Share count change | 32.7% | 10.7% | 40.3% | 48.2% | 13.3% |
| Debt and strength | |||||
| Cash and short-term investments | $577M | $645M | $1.9B | $2.3B | $2.0B |
| Shareholders' equity | $603M | $685M | $1.8B | $2.3B | $1.6B |
| Current ratio | 9.8x | 10.7x | 13.1x | 14.2x | 7.1x |
| Interest coverage | −15,667.3x | — | — | — | −48.8x |
| Returns and quality | |||||
| Return on equity | −34.7% | −38.6% | −34.8% | −29.3% | −58.1% |
| Return on tangible equity | −35.4% | −40.7% | −24.9% | −27.4% | −72.5% |
| Piotroski F-score | 2 | 3 | 3 | 2 | 1 |
| Altman Z'' | 5.7 | 5.6 | 10.3 | 9.6 | −0.0 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$154M
12 insiders
Of sales under plans
100%
$153M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Revolution Medicines, Inc. · RVMD
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $186.99 a share, the company is worth $39.4B.
Source: SEC EDGAR XBRL filings (CIK 0001628171). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.